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Abstract
Background: Hemodialysis (HD) patients are at risk for medication-related problems (MRP). The
MRP number, type, and appearance rate over time in ambulatory HD patients has not been
investigated.
Methods: Randomly selected HD patients were enrolled to receive monthly pharmaceutical care
visits. At each visit, MRP were identified through review of the patient chart, electronic medical
record, patient interview, and communications with other healthcare disciplines. All MRP were
categorized by type and medication class. MRP appearance rate was determined as the number of
MRP identified per month/number of months in study. The number of MRP per patient-drug
exposures were determined using: {[(number of patients) × (mean number of medications)]/
(number of months of study)} /number of MRP identified. Results were expressed as mean ±
standard deviation or percentages.
Results: Patients were 62.6 ± 15.9 years old, had 6.4 ± 2.0 comorbid conditions, were taking 12.5
± 4.2 medications, and 15.7 ± 7.2 doses per day at baseline. Medication-dosing problems (33.5%),
adverse drug reactions (20.7%), and an indication that was not currently being treated (13.5%) were
the most common MRP. 5,373 medication orders were reviewed and a MRP was identified every
15.2 medication exposures. Overall MRP appearance rate was 0.68 ± 0.46 per patient per month.
Conclusion:  MRP continue to occur at a high rate in ambulatory HD patients. Healthcare
providers taking care of HD patients should be aware of this problem and efforts to avoid or
resolve MRP should be undertaken at all HD clinics.
Background
The Institutes of Medicine report highlighting the burden
of medication errors in the United States has brought the
issue of patient safety to the forefront of medical concern.
[1] In the United States healthcare system, medication-
related problems (MRP) cause significant patient morbid-
ity, mortality, and cost. [2-4] MRP are implicated in
16.1% of internal medicine ward hospital admissions.[4]
Surprisingly, 58.9% of admissions could definitely or pos-
sibly be avoided. Once admitted to the internal medicine
ward, greater than 18% of patient deaths can be attributed
to one or more drugs.[5] Adverse drug events contribute
to over 100,000 deaths annually and 25% of ambulatory
patients report experiencing at least one adverse drug
event.[3,6] The economic burden of MRP on the health-
care system is estimated to be in excess of $177 billion.[2]
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Identification and resolution of MRP can occur through
provision of pharmaceutical care. Pharmaceutical care is
defined as a practice in which a pharmacist takes the
responsibility for the patient's drug related needs, and is
held accountable for this commitment.[7] The provision
of pharmaceutical care has made substantial contribu-
tions to patient morbidity and mortality in critical care
and congestive heart failure patients.[8,9]
Currently, there are approximately 350,000 end-stage
renal disease (ESRD) patients in the United States.[1] In
addition to renal failure, these patients have a mean 5
comorbid conditions that require complex medical regi-
mens of a median 8 medications.[10,11]
Several studies have demonstrated that ambulatory
hemodialysis (HD) patients are at risk for medication-
related problems. [12-17] Medication-related problems
can be classified into eight general categories: untreated
indications; improper drug selection; sub-therapeutic dos-
age; overdose; adverse drug reactions; drug interactions;
failure to receive drugs; and drug use without indica-
tion.[18] Factors associated with medication-related prob-
lems in these patients include: more than three concurrent
disease states present; medication regimen changed four
or more times during the past 12 months; five or more
medications in present drug regimen; twelve or more
medication doses per day; history of noncompliance;
presence of drugs that require therapeutic monitoring,
and presence of diabetes.[17] Nearly all HD patients are
risk due to their multiple risk factors present.
Several single-center, short-term studies in ambulatory
HD patients have shown that a mean 4 – 8 MRP exists per
patient.[12-14,17] Although the reports identified numer-
ous MRP of various type and significance, results pre-
sented were obtained with average patient follow up time
of 2.6 ± 1.9 months. It is unknown if the number, type, or
severity of MRP continues at the same rate after a few
months time. This study was conducted to determine the
number, type, severity, and appearance rate of MRP, as
identified through pharmaceutical care activities, in
ambulatory HD patients.
Patients and methods
Over a 10 month period (August 2001 through May
2002) randomly selected patients at our freestanding,
non-profit outpatient dialysis unit (Dialysis Clinic, Inc.,
Kansas City, MO) were evaluated. Patients were eligible
for inclusion if they were greater than 18 years of age,
planned to be continuously enrolled in HD therapy at the
same dialysis clinic throughout the duration of the study,
and agreed to participate with monthly pharmacist visits.
All patients were recruited within a 2 month period and
followed for 10 months.
All patients were typically hemodialyzed for three to four
hours per treatment, three days per week. Patients were
under the care of a private group of nephrologists. Stand-
ard practice at the HD clinic included regular patient visits
by a nephrologist, averaging two to three times per week.
At these encounters, the nephrologist assessed the patient
and made adjustments to the HD prescription or medica-
tion list as deemed appropriate. On a monthly basis,
nephrologists rotate clinic responsibilities among the
group.
At each monthly visit the pharmacist reviewed the patient
chart, electronic medical record including laboratory
measurements, conducted a patient interview with review
of all medications, and communicated with other health-
care disciplines (medicine, nursing, dietary, social work)
about the health status of the patient. With the data col-
lected, the pharmacist then evaluated appropriateness of
medical therapy, identified MRP, and communicated
interventions to the nephrologist via pharmacist progress
note and e-mail correspondence.
Data collected included: patient demographics (age, gen-
der, race, reason for and duration of ESRD), documented
comorbid conditions, medication type and number, and
number of medication doses per day. Medications were
classified similar to that previously reported[11,19] as fol-
lows: anemia (erythropoietin, iron), renal bone disease
(calcium or aluminum salts, sevelamer, vitamin D ana-
logs), cardiac (any agent used for hypertension, conges-
tive heart failure, coronary artery disease, arrhythmia),
cholesterol-lowering (niacin, fibric acid agent, HMG-CoA
reductase inhibitor), endocrine (any agent used for diabe-
tes, thyroid disorders, menopause), anti-infective (includ-
ing antiviral), antithrombotic (agents that may affect
platelet function or prolong coagulation), psychotropic
(antidepressants, antipsychotics), gastrointestinal (hista-
mine-2 receptor antagonist [H2RA], proton pump inhibi-
tor [PPI], promotility agents, laxatives), vitamins,
analgesics, antipruritics, and other (agents with a preva-
lence of less than 10%).
Identified MRP were categorized as: indication without
drug therapy (IWD – patient has a medical problem that
requires medication therapy (an indication for medica-
tion use) but is not receiving a medication for that indica-
tion); drug use without indication (DWI – patient is
taking a medication for no medically valid indication);
improper drug selection (IDS – patient has a medication
indication but is taking the wrong drug); sub-therapeutic
dosage (UD – patient has a medical problem that is being
treated with too little of the correct medication); over-dos-
age (OD – patient has a medical problem that is being
treated with too much of the correct medication); adverse
drug reaction (ADR – patient has a medical problem thatBMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/10
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is the result of a ADR or adverse effect); drug interaction
(DI – patient has a medical problem that is the result of a
medication-medication, medication-laboratory, or medi-
cation-food interaction); failure to receive drug (FRD –
patient has a medical problem that is the result of their
not receiving a medication); and other (O – all those not
able to be classified as above).
Statistics
Results are expressed as mean ± standard deviation or per-
centages (frequency data) as appropriate. MRP appear-
ance rate was determined as follows: the number of MRP
identified per month/number of months in study. The
number of MRP per patient-drug exposures were deter-
mined using the following calculation: { [(number of
patients) × (mean number of medications)]/(number of
months of study)} /number of MRP identified.[17]
Results
Over the ten-month period 145 patients received HD (66
pharmaceutical care group; 79 usual care group). Data
from twelve patients was excluded from analysis due to
patient death (n = 9), transfer (n = 2), or transplant (n =
1) during the study period. Patient demographics are
shown in table 1. Overall, patients were an average of 62.6
± 15.9 years old (range 26–92) and received dialysis for
3.1 ± 2.5 years (range 0 – 13.3). The majority of patients
were male (56%) and African American (78%). Overall,
diabetes mellitus was the primary cause of ESRD (47.8%),
followed by hypertension (22.4%). Patients receiving
pharmaceutical care had 6.4 ± 2.0 (range 3–12) comorbid
conditions, were taking 12.5 ± 4.2 (range 6–21) medica-
tions, and 15.7 ± 7.2 (range 4–34) doses per day at
baseline.
Over the 10-month period the pharmacist reviewed 5,373
medication orders and identified 354 MRP in 66 different
patients. The MRP type and frequency can be seen in Fig-
ure 1. Most commonly, the pharmacist identified medica-
tion-dosing problems (33.5%) or adverse drug reactions
(20.7%) of the time. An indication that was not currently
being treated (IWD) was discovered 13.5% of the time.
The "other" category included interventions aimed at edu-
cation of the patient and/or staff, recommendations due
to lack of supportive laboratory data, and recommenda-
tions due to inappropriate medication treatment dura-
tion. A MRP was identified for every 15.2 medications
reviewed. Overall the MRP appearance rate was 0.68 ±
0.46 per patient per month. At the end of the study period,
0.45 MRP per patient per month were identified (Figure
2).
MRP were classified according to medication class
involved (Table 2). Cardiovascular-related medications
accounted for 29.7% of MRP: 13.3% cardiovascular med-
ication; 8.2% cholesterol lowering medications; and 8.2%
antithrombotic medications (e.g., aspirin). Endocrine
medications accounted for 15.5% of identified MRP.
Nephrology-specific medications (anemia and renal bone
disease medications) accounted for 15% of MRP.
Discussion
We determined that MRP continue to occur at a relatively
high rate month after month in ambulatory HD patients.
At the end of the study period, 0.45 medication-related
problems per patient per month were identified.
Extrapolating these findings to the 246,121 United States
HD population, nearly 111,000 MRP occur each month.
If the same frequency of MRP type were to occur as we
found at our clinic, then each month 35,409 dosing prob-
lems occur, 21,645 adverse drug events occur, and 14,430
Table 1: Patient Demographics
Patient Characteristic All (n = 133) Pharmaceutical Care (n = 66) Usual Care (n = 67) p value
Age (years) 62.8 ± 15.0 62.0 ± 14.3 63.5 ± 15.8 0.64
Male gender (%) 55.6 45.5 65.7 0.22
Race (%)
Black 78.2 71.2 85.1 0.08
Caucasian 17.3 22.7 12.0 0.06
Other 4.5 6.1 3.0 0.66
ESRD Reason (%)
Diabetes mellitus 48.1 60.6 35.8 0.007
Hypertension 21.8 16.7 26.9 0.23
Glomerulonephritis 14.3 12.1 16.4 0.84
Other 15.8 10.6 20.9 0.10
ESRD Duration (years) 3.1 ± 2.5 3.0 ± 1.9 3.3 ± 2.9 0.43
# Medications 11.4 ± 4.2 12.5 ± 4.2 10.2 ± 3.8 0.007
# Comorbid Conditions 5.8 ± 1.9 6.4 ± 2.0 5.1 ± 1.5 0.00003BMC Nephrology 2003, 4 http://www.biomedcentral.com/1471-2369/4/10
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medical problems are not treated with appropriate medi-
cation therapy. These numbers of MRP that could occur
each month appears staggering. However, these patients
have multiple disease states which require multiple med-
ications and intense follow-up. HD patients take a
median 8 medications for an average 5 comorbid condi-
tions.[10,11] Additionally, others have demonstrated that
patients with chronic kidney disease are not prescribed
medications, despite having a medical necessity for phar-
macologic treatment.[20,21] The impact of MRP in other
ESRD populations, i.e., peritoneal dialysis and transplant
patients, warrants further investigation.
Patients having cardiovascular- and endocrine-related
MRP are not surprising given that over 42% of patients
have diabetes and 75.2% of patients have a history of
hypertension.1 Cardiovascular disease (CVD) is the lead-
ing cause of mortality in ESRD patients, accounting for
approximately 50% of deaths.[1] There is much opportu-
nity to increase use of medications with known cardiopro-
tective benefit. Unfortunately, dialysis patients are
infrequently prescribed known cardioprotective medica-
tions. [20-24] The 1998 United States Renal Data System
Annual Data Report (USRDS ADR) stated that 44% of
patients less than 65 years of age with diabetes as the cause
of ESRD were not treated with a hypoglycemic agent. This
number fells 41% for patients over 65 years of age. Data
from the USRDS Dialysis Morbidity and Mortality
(DMMS) Wave-2 study identified 9.7% of patients treated
with an HMG-CoA reductase inhibitor as of day sixty fol-
lowing dialysis initiation.[11] The Dialysis Outcome Prac-
tice Patterns Study (DOPPS) study identified 6.9% of
United States HD patients treated with HMG-CoA reduct-
ase inhibitors.[24] This included 13.8% of patients with
coronary artery disease and 16.1% of patients with a pre-
vious myocardial infarction.
Analysis of USRDS and DOPPS data also show that rela-
tively few patients are prescribed beta-blocker therapy
despite having multiple indications for therapy.[11,22]
Data from the DMMS Wave-2 study showed that 18.7% of
incident dialysis patients with diagnoses of coronary
artery disease, chronic heart failure, and previous myocar-
dial infarction, were prescribed a beta-blocker. This
Frequency distribution of medication-related problems in ambulatory hemodialysis patients Figure 1
Frequency distribution of medication-related problems in ambulatory hemodialysis patients. ADR = adverse drug reactions; DI 
= drug interactions; DWI = drug use without indication; FRD = failure to receive drugs; IWD = indication without drug ther-
apy; O = other; OD = over-dosage; UD = sub-therapeutic dosage; IDS = improper drug selection.
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Number of medication-related problems per patient over time Figure 2
Number of medication-related problems per patient over time.
Table 2: Medication Class Involvement
Medication Class Number (% Occurrence)
Endocrine 55 (15.5)
Cardiac 47 (13.3)
Gastrointestinal 45 (12.7)
Renal bone disease 31 (8.8)
Cholesterol-lowering 29 (8.2)
Antithrombotic 29 (8.2)
Anemia 22 (6.2)
Psychotropic 19 (5.4)
Anti-infective 17 (4.8)
Analgesic 15 (4.2)
Other 15 (4.2)
Vitamins 6 (1.7)
Antipruritic 6 (1.7)
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includes 25% of patients with hypertension, 24% with
coronary artery disease, and 24% with a previous myocar-
dial infarction.[22] Approximately 19% of new HD
patients are given aspirin therapy.[11] The percent of
point prevalent patients prescribed aspirin was higher
than incident patients, suggesting greater use of aspirin
with time on dialysis.[11] Finally, we also performed a
medication use audit at our HD unit.[23] Over 96% of
patients had at least one cardiovascular risk factor present
with an average of 2.4 ± 1.3 cardiovascular risk factor per
patient. Of those patients with a diagnosis of chronic
heart failure, 34.4% were prescribed an ACE inhibitor and
25.0% were prescribed a beta-blocker. Patients with a pre-
vious myocardial infarction were given a lipid-lowering
agent, a nitrate, a beta-blocker, and aspirin 23.1%, 23.1%,
15.4%, and 69.2% of the time, respectively. These studies
highlight that medication prescribing in the treatment of
cardiovascular diseases is in need of improvement in
order to maximize care of the ESRD population.
We have shown that MRP continue to exist at a high fre-
quency in these medically complex patients. To address
this problem, we advocate the inclusion of pharmacists as
a member of the healthcare team taking care of ambula-
tory HD patients. A pharmacist is specially trained to iden-
tify MRP. Pharmacist provided pharmaceutical care
services to resolve MRP has shown to improve medication
compliance, provide drug information, raise awareness of
inappropriate medication prescribing, and improve bio-
chemical and therapeutic responses to medication. [12-
17] This will increase the number of patients achieving
standard of care and improve overall patient care.[12] A
recent review estimated that for every $1 spent on phar-
maceutical care activities in ESRD patients, approximately
$4 to the healthcare system is saved.[25]
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